AbbvVie Under Fire From FDA Over Humira’s Death Complaints
June 12, 2018
Source: Fierce Pharma
567
Various AbbVie products, distributed from the company’s Illinois, North Chicago, manufacturing site, have been tied to death complaints including its biggest hit Humira. According to the FDA the drug manufacturing company has not taken correct action to probe those death complaints
Last year the FDA inspected the AbbVie North Chicago manufacturing site during which time they discovered that the company failed to do a proper investigation on five death complaints received relating to Humira and Venclexta treatments. Though the drug maker reported the deaths, it didn’t collate the historical data of the lots in question. It was later discovered that the lots were tied to another 8 to 10 deaths.
In a statement to FiercePharma, an AbbVie spokeswoman opposed the FDA reports, stating that the company “thoroughly investigates all complaints where a death has occurred during the time of the treatment using our products, and that the written complaint procedures are in place to investigate, analyze and resolve complaints.”
AbbVie’s Humira accounted for 65% of the 2017 total revenue generated in 2017 with global sales of $18.4 billion.
By Ddu
Copyright©2024 Ddu. All rights reserved.
Read more on
- Subscribe to our FREE newsletter Subscribe New EU pharma strategy looks to future-proof healthcare sector, stimulate innovation and boost access to biosimilars and generics November 29, 2020
- Drugdu.com’s 4 most Popular Veterinary APIs and Veterinary medicine Suppliers September 6, 2018
- 4 Pharmaceutical Machinery Packaging and Materials Suppliers September 6, 2018
- 3 ENT Equipment and Medical Anaesthesia Equipment Suppliers September 6, 2018
- Need Natural Plant Extracts? Here are 4 Suppliers! September 6, 2018
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
